Telix Pharmaceuticals Files 6-K Report

Ticker: TLX · Form: 6-K · Filed: Apr 14, 2026

Sentiment: neutral

Topics: foreign-issuer, sec-filing, regulatory-update

TL;DR

Telix Pharma dropped a 6-K on 4/14/26 - check the exhibits for the deets.

AI Summary

Telix Pharmaceuticals Ltd filed a 6-K report on April 14, 2026. The filing includes various exhibits, such as EX-99.1 and EX-99.2, which likely contain important operational or financial updates. The company's mailing and business address are both located at 55 Flemington Road, North Melbourne, C3 3051.

Why It Matters

This filing provides an update from Telix Pharmaceuticals, which could contain material information for investors regarding the company's performance or strategic direction.

Risk Assessment

Risk Level: low — This is a routine filing (6-K) and does not appear to contain specific negative or positive financial news, making the immediate risk level low.

Key Players & Entities

FAQ

What is the primary purpose of a Form 6-K filing?

A Form 6-K is a report of foreign issuer required by the SEC, used to furnish information which the issuer makes or is required to make public pursuant to the laws of its home country.

What are the accession number and filing date for this specific 6-K report?

The SEC Accession No. is 0001140361-26-014495, and the filing date was April 14, 2026.

What types of documents are included in this filing besides the main 6-K form?

This filing includes various exhibits, such as EX-99.1 and EX-99.2, along with several graphic files (JPGs) and a complete submission text file.

Where is Telix Pharmaceuticals Ltd based?

Telix Pharmaceuticals Ltd's mailing and business address is listed as 55 Flemington Road, North Melbourne, C3 3051.

What is the CIK number for Telix Pharmaceuticals Ltd?

The CIK number for Telix Pharmaceuticals Ltd is 0002007191.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on April 14, 2026 regarding Telix Pharmaceuticals Ltd (TLX).

View full filing on EDGAR

View on Read The Filing